Diagnosis and treatment of pulmonary alveolar microlithiasis

EMİRALİOĞLU N., Beken B., ÖZCAN H. N., Yalcin E., Dogru D., Ozcelik U., ...More

PEDIATRICS INTERNATIONAL, vol.58, no.8, pp.805-807, 2016 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 58 Issue: 8
  • Publication Date: 2016
  • Doi Number: 10.1111/ped.13032
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.805-807
  • Keywords: diagnostic imaging, disodium etidronate, pulmonary alveolar microlithiasis
  • Hacettepe University Affiliated: Yes


Pulmonary alveolar microlithiasis (PAM) is a rare genetic disease caused by mutations in sodium-phosphate co-transporter (SLC34A2), which encodes a type 2b sodium phosphate co-transporter. Disease is characterized byintra-alveolar microlith formation of phosphate. Turkey has a high prevalence of PAM. Herein, we report the clinical and radiological findings of three patients diagnosed with PAM and treated with disodium etidronate.